Pregnancy-associated breast cancer (PABC) in young women: a matched case-control study

Figures & data

Table 1. Description of the study group.

	PABC(%) n = 40	Non-PABC(%) n = 80	P-value
Age at diagnosis (year)	29 (25–39)	29 (25–36)	Matched
Age at menarche (year)	14 (11–17)	14 (11–16)	0.344
Duration of disease onset (month)	3.5 (0.1–24)	2.0 (0.1–36)	0.625
Age at first gravidity (year)	26.8	23.5	0.000
Family history			1.000
I.A	2(5)	4(5)
N.A	38(95)	76(95)
Status at diagnosis			ns
Pregnancy	10(25)	N.A
Within 1 year of delivery	30(75)	N.A
Tumor size			0.333
<2 cm	17(42.5)	43(53.8)
≥2 cm	23(57.5)	37(46.2)
Number of metastatic lymph nodes (n)			0.537
0	26(65)	47(58.8)
1–3	6(15)	19(23.7)
> 4	8(20)	14(17.5)
Tumor staging			Matched
I	11(27.5)	22(27.5)
II	23(57.5)	46(57.5)
III	6(15)	12(15)
Histological grade			0.350
1	9(22.5)	10(12.5)
2	23(57.5)	54(67.5)
3	8(20)	16(20)
Ki-67 expression			0.843
< 20%	16(40)	30(37.5)
≥ 20%	24(60)	50(62.5)
HR status			0.221
Negative	17(42.5)	24(30)
Positive	23(57.5)	56(70)
HER2 status			0.692
Negative	23(57.5)	50(62.5)
Positive	17(42.5)	30(37.5)
Triple-negative breast cancer	7(17.5)	10(12.5)	0.579

PABC, pregnancy-associated breast cancer; I.A, applicable; N.A, not applicable; ns. no significant difference; HR, hormone receptor; HER2, human epidermal growth factor receptor 2.

Table 2. Treatment of PABC.

Status at diagnosis	Pregnancy n = 10(%)	Within 1 year of delivery n = 30(%)
Surgery
Breast-conserving	1 (1)	6 (20)
Mastectomy ± reconstruction	9 (90)	24(80)
Neoadjuvant chemo	9 (90)	8(26.7)
Anthracyclines only	5(50)	0
Taxanes only	2(20)	0
Both	3(30)	8(26.7)
Stage of pregnancy
≤12 w	0	N.A
13–24 w	4(40)	N.A
≥25 w	6(60)	N.A
Lactational status	N.A
Yes	N.A	25(83.3)
No	N.A	5(16.7)

Figure 1. Disease-free survival (DFS) estimates for PABC patient vs non-PABC controls.

Figure 2. Overall survival (OS) estimates for PABC patient vs non-PABC controls.

Figure 3. Disease-free survival (DFS) stratified by clinical stages for II-III PABC patients vs non-PABC controls.

Figure 4. Overall survival (OS) stratified by clinical stages status for II-III PABC patients vs non-PABC controls.

Data availability statement

The data supporting the findings of this study are available at: [DOI:10.7910/DVN/SR06ED].